Journal of Chest Surgery

  • 제53권4호
  • /
  • Pages.184-190
  • /
  • 2020
  • /
  • 2765-1606(pISSN)
  • /
  • 2765-1614(eISSN)
대한심장혈관흉부외과학회 (The Korean Society for Thoracic and Cardiovascular Surgery)
권호 표지
DOI QR코드

DOI QR Code

The Role of Modern Radiotherapy Technology in the Treatment of Esophageal Cancer

  • Moon, Sung Ho (Proton Therapy Center, Research Institute and Hospital, National Cancer Center) ;
  • Suh, Yang-Gun (Proton Therapy Center, Research Institute and Hospital, National Cancer Center)
  • 투고 : 2020.06.08
  • 심사 : 2020.07.11
  • 발행 : 2020.08.05
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Radiation therapy (RT) has improved patient outcomes, but treatment-related complication rates remain high. In the conventional 2-dimensional and 3-dimensional conformal RT (3D-CRT) era, there was little room for toxicity reduction because of the need to balance the estimated toxicity to organs at risk (OARs), derived from dose-volume histogram data for organs including the lung, heart, spinal cord, and liver, with the planning target volume (PTV) dose. Intensity-modulated RT (IMRT) is an advanced form of conformal RT that utilizes computer-controlled linear accelerators to deliver precise radiation doses to the PTV. The dosimetric advantages of IMRT enable better sparing of normal tissues and OARs than is possible with 3D-CRT. A major breakthrough in the treatment of esophageal cancer (EC), whether early or locally advanced, is the use of proton beam therapy (PBT). Protons deposit their highest dose of radiation at the tumor, while leaving none behind; the resulting effective dose reduction to healthy tissues and OARs considerably reduces acute and delayed RT-related toxicity. In recent studies, PBT has been found to alleviate severe lymphopenia resulting from combined chemo-radiation, opening up the possibility of reducing immune suppression, which might be associated with a poor prognosis in cases of locally advanced EC.

키워드

참고문헌

  1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623-7. https://doi.org/10.1001/jama.281.17.1623
  2. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74. https://doi.org/10.1200/JCO.2002.20.5.1167
  3. Wang D, Yang Y, Zhu J, Li B, Chen J, Yin Y. 3D-conformal RT, fixed-field IMRT and RapidArc, which one is better for esophageal carcinoma treated with elective nodal irradiation. Technol Cancer Res Treat 2011;10:487-94. https://doi.org/10.7785/tcrt.2012.500225
  4. Nicolini G, Ghosh-Laskar S, Shrivastava SK, et al. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012;84:553-60. https://doi.org/10.1016/j.ijrobp.2011.12.041
  5. Yu WW, Zhu ZF, Fu XL, et al. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol 2014;190:979-86. https://doi.org/10.1007/s00066-014-0636-y
  6. Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:1078-85. https://doi.org/10.1016/j.ijrobp.2012.02.015
  7. Koyama S, Tsujii H, Yokota H, et al. Proton beam therapy for patients with esophageal carcinoma. Jpn J Clin Oncol 1994;24:144-53.
  8. Koyama S, Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas. Clin Cancer Res 2003;9:3571-7.
  9. Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 2010;186:482-8. https://doi.org/10.1007/s00066-010-2079-4
  10. Sugahara S, Tokuuye K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys 2005;61:76-84. https://doi.org/10.1016/j.ijrobp.2004.04.003
  11. Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2008;72:278-87. https://doi.org/10.1016/j.ijrobp.2008.05.014
  12. Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or intensity-modulated radiation therapy. Radiother Oncol 2017;125:48-54. https://doi.org/10.1016/j.radonc.2017.07.034
  13. Welsh J, Gomez D, Palmer MB, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011;81:1336-42. https://doi.org/10.1016/j.ijrobp.2010.07.2001
  14. Zeng YC, Vyas S, Dang Q, et al. Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer: clinical outcome, dosimetry, and feasibility. Strahlenther Onkol 2016;192:913-21. https://doi.org/10.1007/s00066-016-1034-4
  15. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2013;86:885-91. https://doi.org/10.1016/j.ijrobp.2013.04.006
  16. Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res 2015;56:568-76. https://doi.org/10.1093/jrr/rrv001
  17. Lin SH, Merrell KW, Shen J, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol 2017;123:376-81. https://doi.org/10.1016/j.radonc.2017.04.013
  18. Kumagai Y, Monma K, Kawada K. Magnifying chromoendoscopy of the esophagus: in-vivo pathological diagnosis using an endocytoscopy system. Endoscopy 2004;36:590-4. https://doi.org/10.1055/s-2004-814533
  19. Yoshida T, Inoue H, Usui S, Satodate H, Fukami N, Kudo SE. Narrow- band imaging system with magnifying endoscopy for superficial esophageal lesions. Gastrointest Endosc 2004;59:288-95. https://doi.org/10.1016/S0016-5107(03)02532-X
  20. Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus 2019;16:221-45. https://doi.org/10.1007/s10388-019-00674-z
  21. Yamashina T, Ishihara R, Nagai K, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma, Am J Gastroenterol 2013;108:544-51. https://doi.org/10.1038/ajg.2013.8
  22. Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer: comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995;222:654-62. https://doi.org/10.1097/00000658-199311000-00008
  23. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175:47-51. https://doi.org/10.1016/S0002-9610(97)00227-4
  24. Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol 2010;5:707-12. https://doi.org/10.1097/JTO.0b013e3181d3ccb2
  25. Booka E, Takeuchi H, Nishi T, et al. The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Medicine (Baltimore) 2015;94:e1369. https://doi.org/10.1097/MD.0000000000001369
  26. Nakamura M, Kido Y, Hosoya Y, Yano M, Nagai H, Monden M. Postoperative gastrointestinal dysfunction after 2-field versus 3-field lymph node dissection in patients with esophageal cancer. Surg Today 2007;37:379-82. https://doi.org/10.1007/s00595-006-3413-4
  27. Jiang L, Zhao X, Meng X, Yu J. Involved field irradiation for the treatment of esophageal cancer: is it better than elective nodal irradiation? Cancer Lett 2015;357:69-74. https://doi.org/10.1016/j.canlet.2014.11.045
  28. Yamashita H, Takenaka R, Omori M, et al. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol. 2015 Aug 14;10:171. https://doi.org/10.1186/s13014-015-0482-9
  29. Wang X, Miao C, Chen Z, et al. Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer?: a systematic review and meta-analysis. Onco Targets Ther 2017;10:2087-95. https://doi.org/10.2147/OTT.S130285
  30. Lee DY, Moon SH, Cho KH, et al. Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer. Radiat Oncol J 2017;35:241-8. https://doi.org/10.3857/roj.2017.00458
  31. Fu WH, Wang LH, Zhou ZM, Dai JR, Hu YM, Zhao LJ. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol 2004;10:1098-102. https://doi.org/10.3748/wjg.v10.i8.1098
  32. Welsh JW, Seyedin SN, Allen PK, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. J Thorac Oncol 2017;12:375-82. https://doi.org/10.1016/j.jtho.2016.10.013
  33. Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. https://doi.org/10.1056/NEJMoa1112088
  34. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8. https://doi.org/10.1016/S1470-2045(15)00040-6
  35. Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 2012;30:571-6. https://doi.org/10.3109/07357907.2012.700987
  36. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 2013;31:183-8. https://doi.org/10.3109/07357907.2013.767342
  37. Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011;17:5473-80. https://doi.org/10.1158/1078-0432.CCR-11-0774
  38. Wild AT, Ye X, Ellsworth SG, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2015;38:259-65. https://doi.org/10.1097/COC.0b013e3182940ff9
  39. MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia: IV. the critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer 1978;41:108-11. https://doi.org/10.1002/1097-0142(197801)41:1<108::AID-CNCR2820410116>3.0.CO;2-Z
  40. Meyer KK. Radiation-induced lymphocyte-immune deficiency: a factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. Arch Surg 1970;101:114-21. https://doi.org/10.1001/archsurg.1970.01340260018003
  41. Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol 2018;128:154-60. https://doi.org/10.1016/j.radonc.2017.11.028